Clinical Trial

Intranasal LAIV Mucosal Immunity Examination

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines. Intranasal vaccines do not lead to the same changes in the blood that intramuscular vaccines do. Therefore, the investigators want to look at the function of immune (lymphoid) organs that are near the nose. The closest immune organs are the adenoids and tonsils. Mice do not have tonsils allowing for the investigators to answer these questions. Human lymphoid tissue will allow the investigators to better understand the molecular behavior of these cells in humans. The purpose of this protocol is to administer the FDA approved live attenuated influenza vaccine or no vaccine to patients undergoing adenoidectomy and/or tonsillectomy for obstructive sleep apnea prior to surgery and then collect the tissue (adenoid and/or tonsil tissue) that would normally be discarded from surgery. This will allow for improved understanding of what happens after vaccination.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-22; most recent amendment 2025-12-17.
Trial Details
NCT Number NCT07093281
Lead Sponsor University of Maryland, Baltimore
Conditions Impact of Vaccination
Enrollment 25 participants
Start Date 2026-02
Primary Completion 2026-04 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-19